| Gene symbol | RHO | Synonyms | CSNBAD1, OPN2, RP4 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q22.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | rhodopsin | ||||
| GTO ID | GTC3903 |
| Trial ID | NCT06460844 |
| Disease | Retinitis Pigmentosa |
| Altered gene | RHO |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | RTx-015 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-015 in Patients With Retinitis Pigmentosa |
| Year | 2024 |
| Country | United States |
| Company sponsor | Ray Therapeutics, Inc. |
| Other ID(s) | RTx-015-CP-101 |
| Vector information | |||||||
|
|||||||
| Cohort 1 | |||||||
|
|||||||